Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
Returns on capital
Forte Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-113.7%
avg -107.7%
ROIC
-113.9%
avg -64.6%
ROA
-83.8%
avg -59.6%
Analysis
ROA is currently the strongest return metric at -83.8% versus its period average of -59.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Paul A. Wagner | Chief Executive Officer, President & Chairman | USD 1.41M | 56 | 2.50K | 0.02% |
Antony A. Riley | Chief Financial Officer | USD 632.95K | 59 | 750 | <0.01% |
Barbara K. Finck | Senior Medical Clinician & Director | USD 600K | 79 | 31.00K | 0.22% |
Christopher Roenfeldt | Chief Operating Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Aug 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$254,832.78
Sells
0
$0.00
Net Transaction Value
+$254,832.78
Net buying
Most Active
Riley Antony A
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 30, 25Dec 30, 2025 | Riley Antony A Direct | Buy | $254.8K$254,832.78 |
Summary
Insiders reported 1 buys worth $254,832.78 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $254,832.78. Riley Antony A was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Forte Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FBRX's management, answered from reported figures.
Who manages FBRX?
Forte Biosciences, Inc. (FBRX) lists 4 active executives. The top listed executive is Barbara K. Finck, Senior Medical Clinician & Director.
Are FBRX insiders buying or selling?
Recent insider activity shows net buying of $29.71M.
Continue the stock analysis
Jump to another research area for this company.